ADECTO PHARMACEUTICALS, INC.
Biotech · Private
Humanized monoclonal antibody (AD100) targeting ADAM8 for triple-negative breast cancer treatment, paired with an ADAM8 immunohistochemistry diagnostic
- Grants
- $4.7M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $63,490 | |
| Federal grant | Department of Health and Human Services · Phase I · Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $3,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $2,084 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1362 | Irex Pharma LLC | — | — |
| 1363 | CALISTA THERAPEUTICS INC | — | — |
| 1364 | DOOR PHARMACEUTICALS, LLC | — | — |
| 1365 | ADECTO PHARMACEUTICALS, INC. | — | — |
| 1366 | WEATHERWAX BIOTECHNOLOGIES CORPORATION | — | — |
| 1367 | NANO BIOTHERAPEUTICS INC | — | — |
| 1368 | ARTUS THERAPEUTICS INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.